Comments on: Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome

Comments on: Bolder BioTechnology Receives $1.2 Million from NIH to Study Long-Acting G-CSF and GM-CSF Analogs in Treating Acute Radiation Syndrome http://www.rxtimes.com/bolder-biotechnology-receives-1-2-million-from-nih-to-study-long-acting-g-csf-and-gm-csf-analogs-in-treating-acute-radiation-syndrome/ Pharmacy news, jobs, continuing education, community and more. Tue, 08 Nov 2011 18:51:25 +0000 hourly 1 http://wordpress.org/?v=3.2.1